-
Biomarin limits marketing of its FVIII gene therapy, Roctavian
SAN RAFAEL, California, August 5, 2024 — Biomarin has announced that it will limit commercial, research and manufacturing programs for its factor VIII gene therapy...
-
Novel treatments in bleeding disorders: The European Haemophilia Consortium Review
CLICK HERE to access the 2024 ISSUE TWO of the periodic review of novel treatments in hemophilia and other bleeding disorders by the European Haemophilia...
-
Conflicting opinions on gene therapies from Canada’s two HTA agencies
Montreal, July 5, 2024 – Canada’s two health technology assessment (HTA) agencies have made conflicting recommendations on two gene therapies for hemophilia B. Earlier in...
-
The proven importance of data
In the context of the WFH 2024 World Congress, I was invited to present at the Data and Research Workshop on April 21 about how...
-
Access to emicizumab expanded
Montreal, May 24, 2024 – Canadian Blood Services (CBS) announced this week that the provinces and territories have agreed to expand access to emicizumab (Hemlibra)...